FRANKLIN, Tenn. / Apr 16, 2025 / Business Wire / Acadia Healthcare (NASDAQ: ACHC) (“Acadia” or the “Company”) today announced that it will release its first quarter 2025 financial results on Monday, May 12, 2025, after the close of the market. Acadia will conduct a conference call with institutional investors and analysts on Tuesday, May 13, 2025, at 8:30 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference call will be available for 30 days.
The Company also announced that on April 18, 2025, Heather Dixon, the Company’s Chief Financial Officer, will take a brief medical leave to recover from a planned medical procedure. During Ms. Dixon’s brief absence, the Company’s senior finance leadership team, in conjunction with executive management, will oversee Ms. Dixon’s day-to-day responsibilities. The Company currently expects Ms. Dixon to participate in the May 13 conference call.
About Acadia Healthcare
Acadia is a leading provider of behavioral healthcare services across the United States. As of December 31, 2024, Acadia operated a network of 262 behavioral healthcare facilities with approximately 11,850 beds in 39 states and Puerto Rico. With approximately 25,500 employees serving more than 80,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Last Trade: | US$24.53 |
Daily Change: | 0.76 3.20 |
Daily Volume: | 2,714,959 |
Market Cap: | US$2.270B |
August 05, 2025 May 12, 2025 February 27, 2025 October 30, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load